Evolent and American Oncology Network unveil innovative model seeking to improve cancer care while eliminating prior authorization burden

Core Insights - Evolent Health and American Oncology Network (AON) have formed a partnership to enhance cancer care quality and affordability without the need for prior authorization [1][2][5] Partnership Objectives - The partnership aims to improve clinical decision-making through quality-focused interventions and an innovative data analytics platform [2][6] - Providers demonstrating adherence to quality will receive "gold-carding," eliminating the need for prior authorization for most tests and treatments [2][6] Key Components of the Program - Quality Initiatives: Focus on high-impact opportunities to enhance quality and affordability across the care continuum, utilizing provider education and automated reminders [6] - AI-Driven Clinical Insights: The MiBA platform will provide evidence-based insights and personalized treatment plans by analyzing real-time data [6] - Payment Innovation: Development of a payment model that rewards high-quality care, moving away from traditional fee-for-service models [6] - Eliminating Prior Authorization: High-quality treatment pathways will allow providers to bypass prior authorization, expediting treatment and reducing administrative burdens [6] - Care Navigation: AON patients will benefit from Evolent's cancer care navigation program, enhancing support throughout their treatment journey [6] Company Backgrounds - Evolent Health: Specializes in improving health outcomes for complex conditions, recognized for its innovative healthcare solutions [5][7] - American Oncology Network (AON): An alliance of physicians focused on community oncology, promoting value-based care and health equity [7]